{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["85(10)"],"submitter":["Schindewolf M"],"pubmed_abstract":["<h4>Objective</h4>To determine the incidence and causes of skin reactions to the synthetic pentasaccharide fondaparinux.<h4>Patients and methods</h4>Patients who received prophylactic/therapeutic subcutaneous fondaparinux treatment for more than 7 days were prospectively examined for cutaneous adverse effects between September 1, 2008, and April 30, 2009. When indicated, other procedures, such as skin biopsy, allergy testing, and clinical/laboratory assessment for thrombosis and heparin-induced thrombocytopenia, were performed.<h4>Results</h4>Overall, 231 patients were enrolled. No patient developed typical delayed type IV hypersensitivity (DTH) erythematous skin lesions. However, one female patient experienced abdominal pruritus at sites of injection. Histology revealed a mild lymphohisti"],"journal":["Mayo Clinic proceedings"],"pagination":["913-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2947963"],"repository":["biostudies-literature"],"pubmed_title":["Low allergenic potential with fondaparinux: results of a prospective investigation."],"pmcid":["PMC2947963"],"pubmed_authors":["Hecking C","Lindhoff-Last E","Marzi I","Schindewolf M","Boehncke WH","Garbaraviciene J","Kroll H","Scheuermann J","Wolter M","Kaufmann R","Ludwig RJ"],"additional_accession":[]},"is_claimable":false,"name":"Low allergenic potential with fondaparinux: results of a prospective investigation.","description":"<h4>Objective</h4>To determine the incidence and causes of skin reactions to the synthetic pentasaccharide fondaparinux.<h4>Patients and methods</h4>Patients who received prophylactic/therapeutic subcutaneous fondaparinux treatment for more than 7 days were prospectively examined for cutaneous adverse effects between September 1, 2008, and April 30, 2009. When indicated, other procedures, such as skin biopsy, allergy testing, and clinical/laboratory assessment for thrombosis and heparin-induced thrombocytopenia, were performed.<h4>Results</h4>Overall, 231 patients were enrolled. No patient developed typical delayed type IV hypersensitivity (DTH) erythematous skin lesions. However, one female patient experienced abdominal pruritus at sites of injection. Histology revealed a mild lymphohisti","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Oct","modification":"2025-04-05T13:40:54.68Z","creation":"2019-03-27T00:34:30Z"},"accession":"S-EPMC2947963","cross_references":{"pubmed":["20843983"],"doi":["10.4065/mcp.2010.0346"]}}